Shares of the Munich-based biotech MorphoSys today have increased by 2.8% (Frankfurt) reflecting the positive clinical results reported at the American Society of Hematology Congress, held in San Diego in these days. Specifically, the results come from clinical trial L-Mind, aimed at assessing the Mor28 investigational therapy in combination with Celgene’s Revlimid (lenalidomide) in patients with DLBCL (diffuse large B cell lymphoma) who have not undergone chemotherapy yet. The results are extremely positive and demonstrate treatment response in 58% of patients, with a PFS of 16.2 months. Importantly, Roche’s direct competitor at the same congress has reported results from a clinical trial with a similar therapy, Polatuzumab, which however reported a PFS of 12.4 months. The positive results, and the fact that DLBCL affects 130,000 people per year–which could result in at least €800m per year–have encouraged investors to focus on MorphoSys’ shares, which haver made capitalization sky-rocket to a record €3.2bn.